ViGenCell Inc. (KOSDAQ:308080)

Market Cap	124.84B +172.9%
Revenue (ttm)	278.95M
Net Income	-12.56B
EPS	-650.72
Shares Out	20.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	376,140
Average Volume	1,506,346
Open	5,840.00
Previous Close	6,060.00
Day's Range	5,820.00 - 6,300.00
52-Week Range	2,635.00 - 17,360.00
Beta	0.72
RSI	42.67
Earnings Date	n/a

About ViGenCell

ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, Sou...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 64
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308080